Inhibikase Therapeutics, Inc. announced on November 20, 2025, its plans to advance IKT-001 to a global pivotal Phase 3 study for Pulmonary Arterial Hypertension, expecting to start in Q1 2026. The study will involve up to 180 sites worldwide and will feature a two-part adaptive design with a total of 486 patients involved.